(October 2008)
ISSN 0007-0920
Welcome to BJC
Multidisciplinary Journal of Cancer Research
BJC publishes high quality original papers and reviews that make a significant contribution to increasing understanding of the causes of cancer and to improving the treatment and survival of patients.
BJC is proud of its editorial independence, high standards, and tradition of serving the international cancer research community - we are one of the world's leading general cancer journals.
Impact factor 4.635
Trends and inequalities in survival for 20 cancers in England and Wales 1986-2001: population-based analyses and clinical commentaries
This Cancer Research UK supplement provides important new information and commentary on survival rates for the 20 most common cancers diagnosed in England and Wales over a 14-year period from 1986 to 1999. The analyses are based on data collected by cancer registries on 2.2 million cancer patients. The authors have assessed both trends in survival rates over time and inequalities in survival between groups of patients with different levels of deprivation. The unique pairing of epidemiology and expert clinical analysis should provide a complete picture of the state of cancer survival and cancer care in England and Wales.
Click here to view the supplement.
Archive
Coinciding with the release of the first issue of Volume 99 of BJC on 1st July 2008, and the launch of our new website design, BJC, NPG and Cancer Research UK are pleased to announce that all BJC papers will become freely available to readers of this website, 12 months after they are published.
This applies in the first instance to papers published in and after 1999. Please see our Archive page for the details.
Featured Articles
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
Can weight loss prevent cancer?
Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion
Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?
Green tea consumption and lung cancer risk: the Ohsaki study
Determinants of the number of mammography units in 31 countries with significant mammography screening
-
Biomarkers of apoptosis
Fusion in the ETS gene family and prostate cancer
A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204)
Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers
